PB2088: ABBV‐383 IN COMBINATION WITH ANTI‐CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION von Valdes, Cesar Rodriguez, Weisel, Katja, Baz, Rachid, Polepally, Akshanth, Ross, Jeremy A., Jin, Ziyi, D’amico, Kristin, Bueno, Orlando F., Fleming, Leanne Lash, Voorhees, Peter

Volltext

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma von Rodriguez, Cesar, Weisel, Katja, Baz, Rachid C., Polepally, Akshanth R., Ross, Jeremy A., Jin, Ziyi, D'Amico, Kristin, Bueno, Orlando F., Lash Fleming, Leanne, Voorhees, Peter M.

Volltext

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone von Badawi, Mohamed A, Engelhardt, Benjamin, Badillo, Jesus, Suleiman, Ahmed Abbas, Lash Fleming, Leanne, Luo, Yan, Kaufman, Jonathan L., Bahlis, Nizar Jacques, Menon, Rajeev, Salem, Ahmed Hamed

Volltext

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory M... von Kaufman, Jonathan L., Quach, Hang, Baz, Rachid C., Vangsted, Annette Juul, Ho, Shir-Jing, Harrison, Simon J, Plesner, Torben, Moreau, Philippe, Gibbs, Simon D., Medvedova, Eva, Jalaluddin, Muhammad, Ross, Jeremy A., Lash Fleming, Leanne, Luo, Yan, Bahlis, Nizar Jacques

Volltext

P-306 Open-Label Phase 1b Study to Evaluate the Safety and Efficacy of ABBV-383 Monotherapy in Patients With Relapsed or Refractory Light Chain Amyloidosis von Sanchorawala, Vaishali, Kumar, Shaji, Gibbs, Simon, Kastritis, Efstathios, Jaccard, Arnaud, Hoffman, David, Polepally, Akshanth, Hill, Rebecca, Fleming, Leanne Lash, Talati, Chetasi, Bueno, Orlando, Palladini, Giovanni

Volltext

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies von Place, Andrew E, Goldsmith, Kelly, Bourquin, Jean-Pierre, Loh, Mignon L, Gore, Lia, Morgenstern, Daniel A, Sanzgiri, Yeshwant, Hoffman, David, Zhou, Ying, Ross, Jeremy A, Prine, Betty, Shebley, Mohamad, McNamee, Megan, Farazi, Thalia, Kim, Su Young, Verdugo, Maria, Lash-Fleming, Leanne, Zwaan, C Michel, Vormoor, Josef

Volltext

P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma von Kaufman, Jonathan, Quach, Hang, Baz, Rachid, Vangsted, Annette Juul, Ho, Shir-Jing, Abildgaard, Niels, Laubach, Jacob, Ribrag, Vincent, Gibbs, Simon, Medvedova, Eva, Voorhees, Peter, Jalaluddin, Muhammad, Zeng, Jiewei, Ross, Jeremy, Wang, Xifeng, Fleming, Leanne Lash, Bueno, Orlando, Luo, Yan, Bahlis, Nizar

Volltext

Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL von Davids, Matthew Steven, Seymour, John Francis, Roberts, Andrew Warwick, Eichhorst, Barbara, Kipps, Thomas J., Mato, Anthony R., Stilgenbauer, Stephan, Mobasher, Mehrdad, Desai, Monali Bhardwaj, Potluri, Jalaja, Pena, German E., Verdugo, Maria E., Nielsen, Jacqueline, Cyr, Aimee, Lash Fleming, Leanne, Hallek, Michael J.

Volltext

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in... von Kaufman, Jonathan L., Quach, Hang, Baz, Rachid, Vangsted, Annette J., Ho, Shir-Jing, Harrison, Simon J, Plesner, Torben, Moreau, Philippe, Gibbs, Simon D., Medvedova, Eva, Sehgal, Vasudha, Kang, Kingston, Ross, Jeremy A., Lash-Fleming, L. Leanne, Luo, Yan, Bahlis, Nizar J.

Volltext

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies von Place, Andrew E, Goldsmith, Kelly, Bourquin, Jean-Pierre, Loh, Mignon L, Gore, Lia, Morgenstern, Daniel A, Sanzgiri, Yeshwant, Hoffman, David, Zhou, Ying, Ross, Jeremy A, Prine, Betty, Shebley, Mohamad, McNamee, Megan, Farazi, Thalia, Kim, Su Young, Verdugo, Maria, Lash-Fleming, Leanne, Zwaan, C Michel, Vormoor, Josef

Volltext

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) von Wierda, William G, Seymour, John F, Roberts, Andrew W., Kim, Su Young, Lash-Fleming, L. Leanne, Maher, Johnathan, Busman, Todd, Zhou, Lang, Nielsen, Jacqueline, Stilgenbauer, Stephan

Volltext